Employers are quietly reconsidering who foots the bill for GLP-1 weight-loss drugs, and the fallout hits Eli Lilly and Novo Nordisk very differently heading into earnings week.
GLP-1 drug coverage has become a welfare and employment factor for some U.S. workers, as companies weigh their profits against increasingly expensive medical premiums.